DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2015/0307441 A1 Ogrodzinski Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2015/0307441 A1 Ogrodzinski Et Al US 20150307441A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0307441 A1 Ogrodzinski et al. (43) Pub. Date: Oct. 29, 2015 (54) NEW COMPOUNDS AND USES THEREOF A 6LX3L/277 (2006.01) A63L/36 (2006.01) (71) Applicant: Biostatus Limited. Shepshed, A6II 45/06 (2006.01) Leicestershire (GB) (52) U.S. Cl. CPC ............. C07C 225/36 (2013.01); A61 K3I/136 (72) Inventors: Stefan Ogrodzinski, Shepshed, (2013.01); A61K 45/06 (2013.01); A61 K Leicestershire (GB); Paul Smith, 3I/277 (2013.01); G0IN 31/225 (2013.01) Shepshed, Leicestershire (GB); Stephanie McKeown, Shepshed, Leicestershire (GB); Laurence (57) ABSTRACT Patterson, Shepshed, Leicestershire (GB); Rachel Jane Errington, An anthraquinone compound of formula I (Such as the com Shepshed, Leicestershire (GB) pounds of formulae II to X) and processes for making the (73) Assignee: Biostatus Limited. Shepshed, same are provided. Pharmaceutical compositions for use in the treatment of cancer, optionally in combination with an Leicestershire (GB) agent capable of reducing the level of oxygenation of a (21) Appl. No.: 14/420,184 tumour, are also provided. Additionally, an option for com bination with chemotherapeutic and radiotherapeutic modali (22) PCT Filed: Aug. 7, 2013 ties to enhance overall tumour cell kill is provided. Methods for the detection of cellular hypoxia, both in vivo and in vitro, (86). PCT No.: PCT/GB2O13/O52106 are additionally provided. S371 (c)(1), (2) Date: Feb. 6, 2015 Formula I O (30) Foreign Application Priority Data X4 X e sas Aug. 8, 2012 (GB) ................................... 12141693 e as Publication Classification S. 1. X3 X2 (51) Int. Cl. O CD7C 225/36 (2006.01) GOIN3L/22 (2006.01) Patent Application Publication Oct. 29, 2015 Sheet 1 of 20 US 2015/0307441 A1 FGRE AQ4 x 4 days air OC100 x 4 days air Equivalent arrest of cells in G2-M as a function of drug dose in air Patent Application Publication Oct. 29, 2015 Sheet 2 of 20 US 2015/0307441 A1 {RE 12 n a M -------- f -- kat air VP-6 0.8 s 8 -är Jurkat air AQ4N E \ - E O.8 Ye -8-Jurkat air OCOO2 8 a -O-rkat 9 WP-6 S. -A - Bufkat 1% AC4N 5 O. 4. -- Jurkat 1%. OCT002 -C O -- GS. C.O OOO 1 OOOO drug dose (nM x 4 days) Patent Application Publication Oct. 29, 2015 Sheet 3 of 20 US 2015/0307441 A1 GRE 3 t 2 | C A549 air AQ4N is... no noxia Sy. 8 A549 air OCTOR i. 8 -A-A549 3% AC4N O 8 A-A549 3%, OC1002 O. 4. -- A549 1% O2 AC4N St. A549 1% OC1002 O 50 OO Drug dose (ny x 4 days) Patent Application Publication Oct. 29, 2015 Sheet 4 of 20 US 2015/0307441 A1 FR 3. Ai - OC. CO2 3% O2 - OCOO2 1% O2 + OC1002 8t; iivaert arras of ces 1% O2 - ACR4N 2, as a car situg cose ?er hypoxia Patent Application Publication Oct. 29, 2015 Sheet 5 of 20 US 2015/0307441 A1 FGRE 5(A) -- CH-21% OCOO2 -- Do 21% AC&N -- Do-23% OCTOO2 --DoHH23% AQ4N --O-O-O-H2 air OCTO02 -- Doh-2 air AQ4N W O 5 OO Drug conc. (nM) Patent Application Publication Oct. 29, 2015 Sheet 6 of 20 US 2015/0307441 A1 FGRESS) -- SU---4 16 OCOO2 -i-Su-DH-4 1% AC4N N. --S-OH-4.3%OCTOO2 N. - & - S -OH,-43% y AC4N -Q- SJ-3H-4 air OCI 10O2 -8- S-O-3-4 air i AGN .2 SO OO Drug conc. (nw) Patent Application Publication Oct. 29, 2015 Sheet 7 of 20 US 2015/0307441 A1 GRES SO 200 s {Q Air OCT12 A 3% oxygen OCTQ02 C 1% oxygen OCT1002 100 - a a Y- Linear (Air OC1002) s - - - - - - - - Sinear (3% oxygen OC1002) - 3% oxygen. A - - - - - - linear 1% oxygen OCT002) s - - ----- 5 ...--A non-Oxia 9 O 50 OO Drug dose (n\ x 4 days) Patent Application Publication Oct. 29, 2015 Sheet 8 of 20 US 2015/0307441 A1 FGRE Air Control OCOO x 4. days, a s??ando AQ4 x 4 days, 3. 3)) 8 800 Fluorescence intensity (ch. Fo s Ex 633 fam; Em >695 nm) Patent Application Publication Oct. 29, 2015 Sheet 9 of 20 US 2015/0307441 A1 GRE 3 25O 2OO O O 50 OO 150 200 250 Fluorescence intensity (ch. no.; Em-695 nm) Patent Application Publication Oct. 29, 2015 Sheet 10 of 20 US 2015/0307441 A1 FGRE 9A) far-red fluorescence trans ission Fluorescence intensity (ch, no. Ex633 nm, AEm >695 nm) Patent Application Publication Oct. 29, 2015 Sheet 11 of 20 US 2015/0307441 A1 FGRE ( 2. one vehicle only a8a Bicalutamide $2mg/kgiday) 18 5 14 3.2 10 2 A. s 8 O 12 4. 5 8 20 22 24 28 28 Day of Breatment Patent Application Publication Oct. 29, 2015 Sheet 12 of 20 US 2015/0307441 A1 FGE AY Patent Application Publication Oct. 29, 2015 Sheet 13 of 20 US 2015/0307441 A1 FGRE 2{A} ------------- arrrrrrrrrry------------- - r----------- a---------------------------------- A 7 .--Bicatutamide only --- -$o vehicle only --AQ4Nk - OCT1002 only only (50mg/kg) (50mg/kg) $ f 5 4. 3. 3. |- ---- --------------------- - ----- -------- ----- --- Q 5 10 5 2O 25 30 tine days} Patent Application Publication Oct. 29, 2015 Sheet 14 of 20 US 2015/0307441 A1 Figure 28 & OCT1002 only (50mg/kg) B -8-AQ4N only (50mg/kg) 8 is 30 8-Bicalutamide only SN s -m- Cs is 25 s s 20 15 2 e 10 5 O ic----- - - - - - ----------------------------------------------------------------- 0 2 4 6 8 to 12tine 1416 (day) 18 20 22 24 26 28 so Patent Application Publication Oct. 29, 2015 Sheet 15 of 20 US 2015/0307441 A1 FiGRE 3A) --Bicatutamide only ---------------- --&M vehicle only - - - - -8- - - - ACR4-N + 8icalutamide s & - OC1002 + Bicalutamide 4.5 3 Patent Application Publication Oct. 29, 2015 Sheet 16 of 20 US 2015/0307441 A1 FGURE 3(8) 7 : ------&AQ4N - ---------------Bicalutamide poly)------------ B 88:calutamide (exp} y = 0.5788e & CT1002 + Bicalutamide (lin) R = 09915 5 4. -$ $ 8 3 -' & y = 0.001.4x + 0.0728x + 0.58& 8 A. A R* x 0.9882 ... a8 - * - y a 0.0756x + 0.477 O i - - -------------------------- 5 O 5 2O 25 30 time (days) Patent Application Publication Oct. 29, 2015 Sheet 17 of 20 US 2015/0307441 A1 GRE a 1400- or-n Vehicle only re- vehicle - OCOO2 risk 1200- x- 3icalutamide ... " e8.o Sicautamide + OCOO ** S 1. wev" R 800 s s 600 - 400 & M we & S N N S S S - & 8 Tire days post treatinent Patent Application Publication Oct. 29, 2015 Sheet 18 of 20 US 2015/0307441 A1 FRE is (A) Vehicle + OCT1002 (day 7) (8) Bicalutamide + OCT1002 (day 7) Patent Application Publication Oct. 29, 2015 Sheet 19 of 20 US 2015/0307441 A1 FGE 5 - eiggs O 7 14. 2 days Patent Application Publication Oct. 29, 2015 Sheet 20 of 20 US 2015/0307441 A1 F&SR is e 8 se Treatment groups US 2015/0307441 A1 Oct. 29, 2015 NEW COMPOUNDS AND USES THEREOF distant tissues. The development of more malignant meta static tumours is often the precursor to a more significant CROSS REFERENCE TO RELATED disease-related morbidity and the death of the patient. APPLICATION 0005. An attractive approach is the use of a hypoxia acti 0001. The present application claims priority to Great vated prodrug that is non-toxic towards adequately oxygen Britain Patent Application No. 1214169.3, filed Aug. 8, 2012, ated cells found in Systemic tissues, but becomes activated or incorporated herein in its entirety. converted to a cytotoxic form under reduced oxygenation conditions. N-oxide derivatives of cytotoxic alkylaminoan TECHNICAL FIELD thraquinones provide anthraquinone pro-drugs that show almost no cytotoxicity. Importantly these prodrugs are 0002 The present invention relates to novel capable of being converted in vivo under the anaerobic/hy anthraquinone compounds and uses of the same, for example poxic conditions found within neoplastic tissue. Specificity in the treatment of cancer. for the tumour is ensured since systemic tissues, except for tumours, almost never experience oxygen levels low enough BACKGROUND to facilitate the production of the cytotoxic drug. 0003. The therapeutic advantage of an anticancer drug 0006. The anthraquinone N-oxide AQ4N (CAS#136470 depends primarily on the extent to which the agent shows 65-0) is a prodrug that is selectively bioreduced to AQ4, a selective activity for tumour cells and the limiting toxicity potent DNA topoisomerase II inhibitor, in hypoxic tumour towards non-target tissues. Frequently the poor quality of the cells. Previous publications have taught the fundamental vasculature within the growing tumour mass compromises properties and in-vitro I in-vivo characteristics of the prodrug the delivery of drugs, nutrients and oxygen. It is recognised AQ4N (for example, see U.S. Pat. No. 5,132.327). that tumours can have significantly lower median oxygen 0007. The invention seeks to address the need for levels (approximately 1% oxygen; pO2 7.5 mmHg) com improved cancer treatments by providing novel pared to normal tissues (~5.5% oxygen; 42 mmHg) (Sum anthraquinone compounds with a combination of preferable marised from data presented by Brown and Wilson, 2004). In pharmacological and hypoxia-sensing properties. addition, oxygenation levels can vary throughout the tumour due to intermittent opening and closing of tumour blood SUMMARY vessels; poor vascularisation, especially in the tumour core, contributes to oxygen levels often being below 0.1% oxygen 0008. The first aspect of the invention provides a com (1 mm Hg). Tumour cells experiencing varying degrees of pound of Formula I hypoxia, relative to normally perfused tissues, can compro mise treatment effectiveness and contribute to the malig Formula I nancy.
Load more

Recommended publications
  • World Journal of Pharmaceutical Research Sonam Et Al
    World Journal of Pharmaceutical Research Sonam et al . World Journal of Pharmaceutical SJIF ImpactResearch Factor 5.990 Volume 4, Issue 8, 2393-2402. Review Article ISSN 2277– 7105 5-α-REDUCTASE INHIBITORS - A REVIEW Sonam Kaushal* and Manish Sinha Department of Pharmaceutical Chemistry, ASBASJSM College, Bela, Ropar, India. ABSTRACT Article Received on 19 June 2015, 5-alpha reductase is an important enzyme in metabolic pathway of Revised on 10 July 2015, testosterone. Its three subtypes SRD5A1, SRD5A2 andSRD5A3 are Accepted on 02 Aug 2015 responsible for conversion of testosterone to its more potent derivative dihydrotestosterone (DHT). Excess production of DHT leads to *Correspondence prostate cancer and alopecia. The production of DTH can be reduced For Author by inhibiting the 5-alpha reductase enzyme. Several 5-alpha reductase Sonam Kaushal Department of inhibitors were synthesized in the past and are marketed and used for Pharmaceutical the treatment of prostate cancer and baldness. The dosing of these Chemistry, ASBASJSM drugs is between 1 to 5 mg/day. The low dosing of these drugs need College, Bela, Ropar, special attention on quality control and quantitative estimation of drug India. in formulation and biological fluids. The details of 5-alpha reductase inhibitors and the recent developments in their quantitative estimation have been compiled in the presented review. KEYWORDS: 5-α-reductae inhibitors, cancer, quantitative estimation. 1. INTRODUCTION 1. 5-α-Reductase[1, 2, 3] 1.1. 5-α-reductases, also known as 3-oxo-5α-steroid 4-dehydrogenases, are enzymes involved in steroid metabolism. They participate in 3 metabolic pathways: bile acid biosynthesis, androgen and estrogen metabolism.
    [Show full text]
  • Study Protocol: LPCN 1021-18-001
    Oral Testosterone Undecanoate Protocol No. LPCN 1021-18-001 Lipocine Inc. TU, LPCN 1021 675 Arapeen Drive, Suite 202 Salt Lake City, UT-84108 1.0 TITLE PAGE Clinical Study Protocol: LPCN 1021-18-001 Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men. Investigational Product : Testosterone Undecanoate (TU, LPCN 1021) Date of Protocol : 19 February 2019 FDA IND No. : 106476 Development Phase : Phase 3 Testosterone replacement therapy in adult, 18 years or older, males for conditions associated with a deficiency or absence of endogenous Indication : testosterone – primary hypogonadism (congenital or acquired) or secondary hypogonadism (congenital or acquired) Investigator : Multi-Center, US Sponsor : Lipocine Inc. 675 Arapeen Drive, Suite 202, Salt Lake City, Utah – 84108 Tel: +1-801-994-7383 Fax: +1-801-994-7388 Sponsor / : Nachiappan Chidambaram Emergency Contact 675 Arapeen Drive, Suite 202, Salt Lake City, Utah – 84108 Tel: +1-801-994-7383, Ext 2188 Fax: +1-801-994-7388 Email: [email protected] Protocol Version : 06 Confidentiality Statement This document is a confidential communication of Lipocine Inc. Acceptance of this document signifies agreement by the recipient that no unpublished information contained within will be published or disclosed to a third party without prior written approval, except that this document may be disclosed to an Institutional Review Board under the same conditions of confidentiality. Date: 19 February 2019 Confidential Page 1 of 50 Oral Testosterone Undecanoate Protocol No. LPCN 1021-18-001 Lipocine Inc. TU, LPCN 1021 675 Arapeen Drive, Suite 202 Salt Lake City, UT-84108 2.0 SUMMARY OF CHANGES TO PROTOCOL VERSION 2 Version 02 of the LPCN 1021-18-001 study protocol was developed to make the following changes to the study: • Added sexual desire and sexual distress questions to pre-treatment and post-treatment phases of the study.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • Mucoadhesive Drug Delivery Devices and Methods Of
    (19) TZZ___T (11) EP 1 691 746 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/00 (2006.01) A61K 9/00 (2006.01) 27.05.2015 Bulletin 2015/22 A61K 9/16 (2006.01) A61K 38/38 (2006.01) A61K 47/10 (2006.01) (21) Application number: 04813308.6 (86) International application number: (22) Date of filing: 08.12.2004 PCT/US2004/040975 (87) International publication number: WO 2005/055945 (23.06.2005 Gazette 2005/25) (54) MUCOADHESIVE DRUG DELIVERY DEVICES AND METHODS OF MAKING AND USING THEREOF MUKOADHÄSIVE ARZNEIMITTELABGABEVORRICHTUNGEN UND VERFAHREN ZU IHRER HERSTELLUNG UND VERWENDUNG DISPOSITIFS D’ADMINISTRATION DE MEDICAMENTS MUCOADHESIFS ET PROCEDES DE FABRICATION ET D’UTILISATION ASSOCIES (84) Designated Contracting States: • BERG, Eric, P. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Plymouth, MN 55447 (US) HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR (74) Representative: Robertson, James Alexander et al (30) Priority: 08.12.2003 US 527962 P Marks & Clerk LLP 90 Long Acre (43) Date of publication of application: London WC2E 9RA (GB) 23.08.2006 Bulletin 2006/34 (56) References cited: (73) Proprietor: Gel-Del Technologies, Inc. WO-A1-01/28524 WO-A1-99/32107 St. Paul, MN 55114 (US) WO-A1-02/058735 US-A- 5 385 606 US-A- 5 863 554 US-A1- 2002 141 945 (72) Inventors: US-A1- 2003 215 515 • MASTERS, David, B. Hastings, MN 55033 (US) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Cha Kuna Taiteit Un Certain Et Annet Inn
    CHA KUNA TAITEIT US009925232B2UN CERTAIN ET ANNET INN TIN (12 ) United States Patent (10 ) Patent No. : US 9 , 925 , 232 B2 Fein et al. (45 ) Date of Patent: Mar. 27, 2018 ( 54 ) METHODS AND COMPOSITIONS 4 ,505 ,616 A 3 / 1985 Grzelka et al . COMPRISING DESMOPRESSIN IN 4 , 557 , 934 A 12 / 1985 Cooper 4 ,783 ,450 A 11/ 1988 Fawzi et al. COMBINATION WITH A 5 - ALPHA 5 ,023 ,252 A 6 / 1991 Hseih REDUCTASE INHIBITOR 5 ,534 ,496 A 7 / 1996 Lee et al. 6 , 558, 695 B2 5 /2003 Luo et al . (71 ) Applicant: Serenity Pharmaceuticals LLC , 7 , 112 , 561 B2 9 / 2006 Gyurik et al. 7 , 182, 747 B2 2 / 2007 Kwon Milford , PA (US ) 7 ,244 , 703 B2 7 /2007 Gyurik et al. 7 , 335 ,186 B2 2 / 2008 O 'Neil @(72 ) Inventors : Seymour H . Fein , New Canaan , CT 7 , 405 , 203 B2 7 / 2008 Fein (US ) ; Linda Cheng , West Nyack , NY NNNN7 , 579 , 321 B2 8 / 2009 Fein (US ) ; Maria Cheng , Chestnut Ridge , 7 , 799 , 761 B2 9 / 2010 Fein NY (US ) ; Samuel Herschkowitz , 8 , 143 , 225 B2 3 / 2012 Fein 8 , 399 , 410 B2 3 / 2013 Herschkowitz et al. Brooklyn , NY (US ) 9 , 375 , 530 B2 6 /2016 Herschkowitz et al . 9 , 539 ,302 B2 1 / 2017 Fein @(73 ) Assignee : Serenity Pharmaceuticals , LLC , 2004 / 0138098 A1 * 7 / 2004 Fein . 514 / 2 Milford , PA (US ) 2009 /0042970 A1 * 2 / 2009 Herschkowitz et al . .. .. 514 / 423 2010 /0056436 A 3 / 2010 Fein 2010 /0160214 AL 6 /2010 Fein et al . ( * ) Notice : Subject to any disclaimer , the term of this 2012 / 0015880 A11 / 2012 Fein patent is extended or adjusted under 35 2012 /0149643 A1 * 6 /2012 Fein .
    [Show full text]
  • The 5 Alpha-Reductase Isozyme Family: a Review of Basic Biology and Their Role in Human Diseases
    Hindawi Publishing Corporation Advances in Urology Volume 2012, Article ID 530121, 18 pages doi:10.1155/2012/530121 Review Article The 5 Alpha-Reductase Isozyme Family: A Review of Basic Biology and Their Role in Human Diseases Faris Azzouni, Alejandro Godoy, Yun Li, and James Mohler Department of Urology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA Correspondence should be addressed to Faris Azzouni, [email protected] Received 15 July 2011; Revised 11 September 2011; Accepted 27 September 2011 Academic Editor: Colleen Nelson Copyright © 2012 Faris Azzouni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Despite the discovery of 5 alpha-reduction as an enzymatic step in steroid metabolism in 1951, and the discovery that dihydrotestosterone is more potent than testosterone in 1968, the significance of 5 alpha-reduced steroids in human diseases was not appreciated until the discovery of 5 alpha-reductase type 2 deficiency in 1974. Affected males are born with ambiguous external genitalia, despite normal internal genitalia. The prostate is hypoplastic, nonpalpable on rectal examination and approximately 1/10th the size of age-matched normal glands. Benign prostate hyperplasia or prostate cancer does not develop in these patients. At puberty, the external genitalia virilize partially, however, secondary sexual hair remains sparse and male pattern baldness and acne develop rarely. Several compounds have been developed to inhibit the 5 alpha-reductase isozymes and they play an important role in the prevention and treatment of many common diseases.
    [Show full text]
  • I Regulations
    23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
    [Show full text]
  • Role of 5 Alpha-Reductase Inhibitors in the Management of Prostate Cancer
    REVIEW Role of 5 alpha-reductase inhibitors in the management of prostate cancer Steven J Hudak1 Abstract: Prostate cancer is one of the most complex and enigmatic oncologic problems in Javier Hernandez1 medicine. It is highly prevalent, particularly in elderly males. Unfortunately, its generally Ian M Thompson2 protracted and variable clinical course and high association with treatment-related morbidity raise serious questions about the ideal treatment strategy for the individual patient. 5 alpha- 1Urology Service, Department of Surgery, Brooke Army Medical reductase (5AR) inhibitors have a dramatic effect on benign prostatic disease with low toxicity. Center, Fort Sam Houston, TX, USA; Thus, there is much interest in the potential role of 5AR inhibitors in the prevention and 2 Department of Urology, University treatment of prostate cancer. Finasteride is the only agent that has been shown in a randomized of Texas Health Science Center at San Antonio, San Antonio, TX, USA clinical trial to decrease the risk of prostate cancer with a reduction of almost 25%. Additionally, a recent analysis of the Prostate Cancer Prevention Trial (PCPT) has found that finasteride improves the performance characteristics of prostate-specific antigen (PSA) blood test as a screening tool for prostate cancer, for both cancer detection as well as for detection of high risk disease. Finally, 5AR inhibitors have been studied as a component of multimodal therapy for all stages of prostate cancer, with the goal of improving oncologic outcomes while avoiding the toxicity of medical and surgical castration. Keywords: prostate cancer, 5-α-reductase inhibitors, finasteride, dutasteride, chemoprevention Introduction Prostate cancer is the most common noncutaneous malignancy in males.
    [Show full text]
  • Available Online Through ISSN 2229-3566
    Dasgupta Debjani et al / IJRAP 2011, 2 (3) 839-844 Research Article Available online through www.ijrap.net ISSN 2229-3566 INHIBITION OF TYPE I 5α-REDUCTASE BY MEDICINAL PLANT EXTRACTS 1 2 2 2 1* Patil Vijaya , Samuel Grace , Mirapurkar Shubhangi , R. Krishna Mohan , Dasgupta Debjani 1Department of Biochemistry, The Institute of Science, Mumbai - 400032, India 2Board of Radiation and Isotope Technology, Navi Mumbai-400705, India Received on: 12/05/2011 Revised on: 10/06/2011 Accepted on: 16/06/2011 ABSTRACT Type I 5α-reductase has been implicated in skin disorders such as acne, hirsutism and male pattern baldness and its inhibition offers a potential treatment for these disorders. The aim of this study was to investigate the inhibition of type I 5α-reductase activity by extracts from Indian medicinal plants. Plant extracts were screened and selected based on their ability to inhibit Propionibacterium acnes and Staphylococcus epidermidis. Since type I 5α-reductase metabolises testosterone to Δ4-androstene-3, 17-dione, the activity of enzyme was determined using RIA for testosterone and Δ4-androstene-3, 17-dione. It was found that methanolic extract of Embelia ribes was a potent inhibitor of type I 5α-reductase (IC50:100μg/mL). Extracts of Vitex negundo, Terminalia chebula, and Terminalia bellerica which also inhibited type I 5α-reductase (IC50: 200-390 μg /mL). Therefore herbal formulation of these plant extracts may be used in the treatment of skin disorders involving type I 5α-reductase. KEYWORDS: Type I 5α-reductase; acne; MBC; medicinal plants *Corresponding author Debjani Dasgupta, Department of Biochemistry, The Institute of Science, 15 Madame Cama Road, Mumbai - 400032, India E-mail: [email protected] INTRODUCTION growth of P.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]